National Cancer Institute Home at the National Institutes of Health |
Please wait while this form is being loaded....
The Applied Research Program Web site is no longer maintained. ARP's former staff have moved to the new Healthcare Delivery Research Program, the Behavioral Research Program, or the Epidemiology & Genomics Research Program, and the content from this Web site is being moved to one of those sites as appropriate. Please update your links and bookmarks!

Publication Abstract

Authors: Quon JL, Yu JB, Soulos PR, Gross CP

Title: The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer.

Journal: J Geriatr Oncol 4(1):9-18

Date: 2013 Jan

Abstract: OBJECTIVES: Neoadjuvant and concurrent androgen deprivation therapy (ncADT) is recommended for men with high-risk prostate cancer, but not low-risk cancer or short life expectancy. It is unclear whether the use of ncADT among older men in the community setting is aligned with the potential for clinical benefit. MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare database to assess patterns of ncADT use among men diagnosed with prostate cancer during 2004-2007 who received radiation therapy. Men were stratified according to tumor risk groups and life expectancy. We used logistic regression to identify factors associated with ncADT use within each risk group. RESULTS: There were 10,686 men in the sample (mean age 74.2 years; 83.4% white). The use of ncADT was 80.7%, 54.1%, and 27.8% in the high-, intermediate-, and low-risk groups, respectively. Men with a life expectancy<5 years had higher rates of ncADT use than men with a life expectancy‚Č•10 years in all risk groups. Within each risk group, advancing age was associated with higher likelihood of receiving ncADT (odds ratio for men aged 80-84 compared to 67-69=1.93 (95% CI 1.37-2.70); 1.51 (95% CI 1.22-1.87); and 1.71 (95% CI 1.14-2.57) for high-, intermediate-, and low-risk groups, respectively). CONCLUSION: ncADT use is not consistent with guideline recommendations and is more frequent among men who are older, have shorter life expectancy, and are less likely to benefit from therapy.

Last Modified: 03 Sep 2013